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Abstract
Chronic infections caused by persistent pathogens represent an important health problem. Here, we establish a simple
practical mouse Salmonella infection model for identifying bacterial maintenance functions that are essential for
persistency. In this model, a substantial fraction of Salmonella survived even several days of treatment with a potent
fluoroquinolone antibiotic indicating stringency of the model. Evaluation of twelve metabolic defects revealed dramatically
different requirements for Salmonella during persistency as compared to acute infections. Disrupted synthesis of
unsaturated/cyclopropane fatty acids was the only defect that resulted in rapid Salmonella clearance suggesting that this
pathway might contain suitable targets for antimicrobial chemotherapy of chronic infection.
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Introduction
Persistent pathogens represent a major problem for control of
infectious diseases [1]. Extensive drug tolerance of persisters to all
available antimicrobials often leads to treatment failures and
relapse. Persistent pathogens may adopt a non-replicating
dormant stage with no requirement for macromolecular synthesis
comprising most current antimicrobial targets [2]. As a conse-
quence, such dormant stages are tolerant to most antibiotics. In
addition, low metabolic activity during dormancy might minimize
vulnerability to perturbation. In fact, it remains unclear if dormant
persisters have any essential maintenance requirements for
survival that could provide opportunities for eradication through
antimicrobial chemotherapy.
Various in vitro models have been used as an approximation of
chronic infection with dormant persisters. Data obtained with
these models revealed differential perturbation effects depending
on the particular model and the respective pathogen [3,4,5,6,7,8].
As an example, proton motive force-driven ATP synthesis has
been shown to be essential for Mycobacterium tuberculosis survival in
a hypoxia in vitro model [9]. Indeed, inhibition of ATP synthase
accelerates mycobacterial eradication in patients [10]. On the
other hand, diminishing ATP levels can actually promote E. coli in
vitro persister formation [1]. Additional in vivo models could help
to compare persister maintenance requirements under relevant
conditions. However, except for Mycobacterium tuberculosis, practical
in vivo persistency models are largely lacking.
Salmonella enterica can cause diarrhea or systemic disease called
typhoid/paratyphoid fever. A substantial fraction of systemically
infected individuals develops asymptomatic chronic infection
[11,12]. In many cases, Salmonella persists in biofilms on gallstones
but persisting Salmonella have also been detected in liver [13] and
lymph nodes [14]. Surgical removal of gallstones is required for
successful treatment of Salmonella in gallstones biofilms, while
extended treatment with potent fluoroquinolone antibiotics is
recommended for treatment of chronic Salmonella tissue coloniza-
tion [15].
In genetically resistant mice, Salmonella cause an acute infection
with exponential Salmonella proliferation. However, after Salmonella
peak colonization and partial clearance Salmonella persist at low
levels and this can cause relapses [14]. Genetic screens have
identified some factors that might support chronic Salmonella
survival in this model [12]. However, Salmonella mutants defective
for genes relevant during the initial acute phase would be lost early
on without reaching persistency. This problem could be
circumvented using inducible gene cassettes but this is impractical
for testing many candidate genes.
In this study, we used a simple chronic mouse Salmonella
infection model in which a substantial Salmonella subpopulation
survived without previous exponential proliferation. Interestingly,
Salmonella survived even prolonged treatment with a fluoroquino-
lone antibiotic thus mimicking treatment failures. In this stringent
in vivo model, almost all tested Salmonella activities were dispens-
able confirming extensive resilience of persistent pathogens against
perturbation. On the other hand, the data also revealed a few
novel candidate targets that could be explored for their suitability
to control chronic infections.
Results
Persistency Model using Salmonella purA ssaGH
Wildytpe Salmonella SL1344 grew exponentially in spleen of
infected genetically susceptible BALB/c mice (Figure S1A). To
generate a practical Salmonella persistency model, we constructed
a Salmonella SL1344 derivative that survived but largely failed to
proliferate in systemically infected mice. Specifically, we combined
two mutations that had previously been shown to impair Salmonella
in vivo growth: purA which blocks adenosine biosynthesis [16], and
ssaGH which inactivates the SPI-2 (Salmonella pathogenicity island
2)-associated type three secretion system required for intracellular
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Salmonella growth and virulence [17]. Both purA and SPI-2
mutations have previously been shown to result in long-term
persistence with minimal acute virulence, but our initial charac-
terization revealed some in vivo proliferation of the individual
mutants after i.v. administration (Figure S1B). In contrast, the
double mutant Salmonella purA ssaGH was initially largely cleared
from spleen and liver (Figure S1C) consistent with early killing
during acute salmonellosis [18], but maintained largely constant
bacterial tissue loads thereafter (Fig. 1A, B) suggesting limited net
growth.
To determine the suitability of this model for evaluating
antimicrobial targets during persistency, we treated infected mice
with the antibiotic enrofloxacin. This antibiotic belongs to the
fluoroquinolone class, which is uniquely effective against non-
growing bacteria in vitro [19], and the treatment of choice for
human persistent salmonellosis although effective therapy might
require several weeks of treatment [15]. Enrofloxacin has been
shown to be well absorbed after oral administration, with
penetration into all tissues [20]. Indeed, enrofloxacin is the most
effective drug in the mouse typhoid fever where it diminishes
wildtype Salmonella loads in spleen and liver to levels below the
detection threshold within one to two days of treatment although
relapses occur unless treatment is continued for several days
indicating some residual Salmonella persistence [21,22]. In our
persistency model, the same enrofloxacin treatment initially
diminished spleen loads of Salmonella purA ssaGH, but in contrast
to previous findings for wildtype Salmonella, a substantial surviving
subpopulation of Salmonella purA ssaGH stabilized within two days
and remained clearly detectable during at least four days of
treatment (Fig. 1A). Liver loads continuously decreased during
prolonged treatment suggesting somewhat different Salmonella
physiological states and/or differential pharmacokinetics in the
two host tissues. We determined MIC (minimal inhibitory
concentration) values of the inocculum and ten clones recovered
from spleen and liver of two different mice after four days of
enrofloxacin treatment. All clones were enrofloxacin sensitive with
the same MIC value of 0.06 mg l21 indicating that Salmonella
persisted because of partial tolerance or limited antibiotic
availability, but not emergence of resistant mutants. The sub-
stantially increased persistence of Salmonella purA ssaGH during
enrofloxacin treatment indicated that our model offered a practical
approach to study treatment failures during persistency. Enro-
floxacin efficacy also provided a suitable benchmark for potential
new Salmonella persistency targets.
Salmonella Defects with Minor Persistency Phenotypes
Only a small number of Salmonella genes are absolutely essential
for Salmonella survival and growth in host tissues during acute
salmonellosis [23]. Some of these genes might also be relevant for
Salmonella persistency. To test this hypothesis we transduced 12
mutations into the parental Salmonella purA ssaGH strain, and
determined persistence capabilities of the resulting strains in
competitive infections with mixtures with the parental strain. At
day 7 post infections, most strains had small colonization defects
compared to the parental strain as indicated by competitive indices
that were close to 1. These data suggested that most tested genes
had only minor impact on Salmonella persistency in our model
despite their crucial importance during acute infections (Fig. 2).
As an example, ubiC encoding chorismate lyase is required for
ubiquinone biosynthesis. During acute infection, Salmonella ubiC is
completely cleared from infected mice within one day indicating
absolute essentiality [23]. In striking contrast, Salmonella purA ssaGH
ubiC survived at high levels indicating dispensability of ubiquinone-
mediated oxidative respiration during persistency. Similarly,
functional ATPase is essential for acute Salmonella virulence [24],
but we found it to be fully dispensable during persistency. This was
in striking contrast to various Mycobacterium tuberculosis models that
suggest ATPase to be a particularly attractive target for this
pathogen [9,10]. Another case with strikingly different relevance in
acute [25] vs. persistent Salmonella infections was recA involved in
DNA repair. More expectedly, trxA encoding a thioredoxin
essential for SPI-2 function [26], had no detectable role in
Salmonella purA ssaGH presumably because SPI-2 was already
inactive in this strain.
Polyphosphate biosynthesis or fatty acid degradation were
known to be largely dispensable during acute infection but had
Figure 1. Colonization kinetics of Salmonella enterica serovar Typhimurium purA ssaGH in systemically infected BALB/c mice. Data are
shown for spleen (A) and liver (B) of individual untreated mice (open circles), and mice that were treated from day two post infection with
enrofloxacin (filled circles). Statistical significance of clearance at day 6 compared to day 4 were determined by t-test of log-transformed data (**,
P,0.01; n.s., not significant).
doi:10.1371/journal.pone.0042007.g001
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some role in other chronic Salmonella infection models [27,28].
However, in our stringent model both activities had weak effects
indicating their dispensability for persistency. All these negative
results suggested a severely limited number of suitable targets for
control of persistent Salmonella infections.
Salmonella Defects with Moderate Persistency
Phenotypes
In contrast to all these cases, two mutations, asd and gutQ yrbH,
showed moderate phenotypes in our model (Fig. 3). asd encoding
aspartate semialdehyde dehydrogenase is required for biosynthesis
of the cell-wall peptidoglycan component diaminopimelic acid. A
Salmonella asd strain spontaneously lyses in vitro and is completely
cleared within one day from systemically infected mice [23].
However, Salmonella purA ssaGH asd was only partially cleared
during the first day post infection which might reflect residual
proliferation of some Salmonella and/or difficulties in establishing
a suitable systemic niche [18]. Thereafter, this strain persisted at
slowly declining levels in spleen. This could reflect non-essentiality
of cell-wall synthesis for non-growing bacteria [19]. In contrast,
liver loads rapidly declined suggesting a substantial fraction of
Salmonella purA ssaGH with active cell-wall turnover/growth in
liver. Similarly, Salmonella purA ssaGH gutQ yrbH that required
supplementation with the lipopolysacharide precursor arabinose-
5-phosphate to grow in vitro [29] and was highly attenuated
during acute infections (our unpublished data), maintained high
levels in spleen but was cleared from liver suggesting limited
lipopolysaccharide demands during Salmonella persistency. Both
genes thus were unsuitable as targets.
Two additional mutants had very severe colonization defects
but still maintained stable small loads indicating non-essentiality
for seven day persistence. Salmonella purA ssaGH ribB defective for
3,4-dihydroxy-2-butanone 4-phosphate synthase which is involved
in riboflavin biosynthesis, was cleared within one day post
infection to very low levels in both spleen and liver, but stabilized
thereafter particularly in liver. This might reflect differential
availability of host riboflavin supplementation in these two tissues.
Importantly, these data showed that Salmonella with defective
riboflavin biosynthesis can survive in vivo for extended periods.
Another strain that was rapidly cleared from spleen had a defect in
iscS encoding cysteine desulfurase involved in repair of iron-sulfur
clusters and tRNA modification [30]. This mutant also dropped to
very low loads in liver but still maintained detectable loads at seven
days post infection.
b-ketoacyl-ACP Synthase I Essentiality for Salmonella
Persistency
Finally, there was a single mutant with a more promising
phenotype (Fig. 4A). Salmonella purA ssaGH fabB defective for b-
ketoacyl-ACP synthase I required for biosynthesis of unsaturated
fatty acids and cyclopropane fatty acids, was progressively cleared
from both liver and spleen. During clearance, residual Salmonella
purA ssaGH fabB were recovered from mice mostly as small-colony
variants. Withdrawal of fatty acid supplementation in vitro
similarly enriched small-colony variants of this strain (Fig. 4B),
suggesting that reduced growth and metabolism might enhance
survival of this mutant when external fatty acids are unavailable.
However, even small-colony variants were rapidly cleared from
mouse tissues. Small colony variants usually reflect decreased
growth rate which can be caused by diverse Salmonella defects such
as dimished respiratory activity [31]. Elucidation of the actual
mechanisms that caused our SCV’s was difficult because small-
colony variants of Salmonella fabB generated in vivo or in vitro
quickly reverted to fast growth upon sub-culturing in presence of
oleic acid supplementation.
To test the suitability of this target for antimicrobial chemo-
therapy, we administered thiolactomycin [32], a slow onset
inhibitor of b-ketoacyl-ACP synthase I that is effective in mouse
infection models with extracellular pathogens [33]. However, safe
doses did not diminish Salmonella purA ssaGH loads in spleen (data
not shown). This could reflect the low target affinity of this
inhibitor and/or poor delivery to Salmonella that persist in-
tracellularly in infected macrophages [14,21].
Discussion
Chronic infections represent a major health problem. Eradica-
tion often requires long-term treatment that causes compliance
problems, facilitates resistance development, and often fails to
prevent relapse. Many chronic infections are likely to be caused by
persistent pathogens in a dormant state with minimal cellular and
metabolic activities. In fact, it remains unclear if such dormancy
has any basal maintenance requirements that could be targeted for
therapy. Various in vitro and in vivo models have been established
to determine requirements of persistent pathogens. However,
results depend on the particular model and it remains unclear how
well these models mimic relevant conditions during chronic
infections. It is likely that even within one infected host tissue,
various microenvironments exist that might induce distinct forms
of persistency [34,35].
Here we established a simple Salmonella mouse infection model
in which Salmonella with dual metabolic and virulence defects
persisted at constant tissue loads without an initial acute infection
that hampers functional analysis in a more natural Salmonella
infection in genetically resistant mice [12]. Indeed, in this model
a substantial fraction of such Salmonella reached a non-proliferating
state with minimal cell wall turnover within one day post infection
in spleen, and a substantial Salmonella subpopulation even survived
chronic treatment with a fluoroquinolone. This was surprising
since the same treatment diminishes wildtype Salmonella loads in
spleen to non-detectable levels [21,22], and since fluoroquinolones
are the most potent, but still only partially effective antibiotic to
Figure 2. Competitive indices (CI) of various Salmonellamutants
vs. the parental Salmonella purA ssaGH strain in infected spleen
(open circles) and liver (filled circles). Data are shown for
individual mice at day seven post infection. A competitive index of 1
indicates equal colonization capabilities of mutant and parental strains.
Statistical significance was determined by t-test of log-transformed
data. Spleen colonization of mutants ppk, recA, trxA, ubiC, and fadD fadK
was significantly lower compared to the parental strain (P,0.05). Liver
colonization of mutants ppk, recA, and fadD fadK was significantly lower
compared to the parental strain (P,0.05).
doi:10.1371/journal.pone.0042007.g002
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eradicate persistent salmonellosis [15] and non-growing bacteria in
general [2,19]. These data suggested that our model represented
a stringent test for identifying targets that might be useful in
clinically relevant settings. On the other hand, the emergence of
small-colony variants of a fabB mutant suggested that in this model
persistent Salmonella still had some metabolic activities that could
be diminished to relax residual maintenance requirements.
Salmonella in liver remained sensitive to fluoroquinolone
treatment and required continuous de novo cell wall synthesis.
These data suggested that despite purine auxotrophy and in-
activity of the SPI-2 type III secretion system, liver microenviron-
ments might permit residual Salmonella proliferation in this tissue.
Liver colonization was therefore less suitable as readout for
Salmonella maintenance requirements during persistency. On the
other hand, distinct Salmonella microenvironments in this organ
provided complementary information for target evaluation. As an
example, liver seemed to provide conditions that enable at least
partial survival of Salmonella mutants defective for riboflavin
biosynthesis or repair of iron-sulfur clusters, in contrast to
conditions in spleen. Antimicrobial chemotherapy should eradi-
cate Salmonella from all host organs including liver suggesting that
the corresponding targets might be unsuitable.
The Salmonella metabolic network contains more than 1200
different enzymes that could all represent potential antimicrobial
targets. However, only a very small number of these enzymes are
sufficiently important for Salmonella physiology to qualify as
potentially suitable targets to control acute infections [23].
Interestingly, the data from this study suggested that almost all
of these targets might be unsuitable to treat persistent infections
indicating strikingly different Salmonella requirements for survival
as compared to growth in host tissues. Activities that were
absolutely essential during acute infection, but dispensable during
Figure 3. Colonization kinetics of four compromised mutants in spleen (open circles) and liver (filled circles). Small residual
colonization levels after seven days of infection suggested that all shown genes contributed to Salmonella survival but were not absolutely essential.
Statistical significance of clearance at day 7 compared to day 1 in spleen was determined by t-test of log-transformed data (***, P,0.001).
doi:10.1371/journal.pone.0042007.g003
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persistency, include cell wall synthesis, ubiquinone-dependent
aerobic respiration, proton motive force-dependent ATP synthesis,
translational accuracy, DNA repair, and thioredoxin-mediated
redox balance. Dispensability of PMF-driven ATP synthesis
highlighted the stringency of our model but might also reflect
differences between Salmonella and other pathogens. In addition,
activities that play important roles in other persistency models
including fatty acid degradation and polyphosphate storage were
also dispensable in our model. These data indicate that Salmonella
purA ssaGH had limited requirements for extended in vivo survival.
We found only a single defect, inactive biosynthesis of
unsaturated fatty acids and cyclopropane fatty acids that resulted
in clearance to non-detectable tissue loads within a few days.
Interestingly, clearance kinetics for defective mutants were faster
compared to the best current antimicrobial drug enrofloxacin for
chronic salmonellosis suggesting that the corresponding targets
could potentially help to improve treatment of such disease. It is
possible that defective fatty acid biosynthesis could result in
accumulation of toxic intermediates although such toxic inter-
mediates have not yet been described in the respective pathway
and the mutant grows normally in vitro if supplemented with oleic
acid. Flux-Balance Analysis [36] of a genome-scale metabolic
model [37] predicted additional expected essential genes in the
fatty acid biosynthesis pathway (accA, accB, accC, accD, acpP, fabA,
fabD, fabG, fabI) but no other pathways reflecting redundancy in
providing required precursors such as malonyl-CoA, NADPH,
and NADH.
Unsaturated fatty acids and their derivatives cyclopropane fatty
acids together comprise about one-half the Salmonella fatty acid
content [38]. Essentiality of de novo synthesis could suggest
continuous internal turnover, damage, and or loss to the
environment. Damage/loss of membranes has previously been
proposed as a potential strategy to control persisters [39]. Reactive
oxygen species can readily damage mammalian polyunsaturated
fatty acids, but bacterial unsaturated fatty acids that usually
contain only a single double bond are refractory to oxidative
damage [40]. Alternatively, membranes could also be lost by
shedding outer membrane vesicles [41]. On the other hand,
continuous synthesis of another outer membrane component,
lipopolysaccharide may not be needed for Salmonella persistence
based on the slow clearance of Salmonella purA ssaGH gutQ yrbH
from infected spleen (Fig. 3). Further studies are needed to clarify
the function of de novo fatty acid synthesis and the impact of the
host immune response on fatty acid requirements during Salmonella
persistency. It is also important to note that host fatty acids (both
saturated and unsaturated) might be sufficiently available in other
infectious disease models, especially in case of extracellular
pathogens [42].
In conclusion, we established a practical, highly stringent in vivo
persistency model. Data obtained with this model revealed that
key metabolic activities that are essential during acute salmonel-
losis might be dispensable during persistent Salmonella infections.
On the other hand, at least some Salmonella metabolic activities
might be crucial for persistency and the model could help to
identify additional requirements in subsequent studies.
Materials and Methods
Bacterial Genetics
We used strain Salmonella enterica serovar typhimurium SL1344
hisG xyl [43] as parental wild type strain. Salmonella mutants were
constructed by lamda red- recombinase mediated allelic re-
placement [44] followed by general transduction using phage
P22 int [45]. Resistance cassettes were flanked with FRT sites for
removal using FLP recombinase [44]. All strains were cultivated at
37uC in Lennox LB medium containing 90 mg/ml streptomycin
and 50 mg/ml kanamycin, 20 mg/ml chloramphenicol, and/or
100 mg/ml ampicillin, as appropriate. Auxotrophs were supple-
mented with 40 mg/ml riboflavin (ribB), 0.1% oleate (fabB), 50 mg/
ml diamino pimelic acid (asd), 15 mM D-arabinose-5-phosphate/
Figure 4. Clearance of Salmonella purA ssaGH fabB from infected mice. A) Colonization kinetics in spleen (open circles) and liver (filled circles).
Similar results were obtained in three independent experiments. Statistical significance of clearance at day 7 compared to day 1 were determined by
t-test of log-transformed data (***, P,0.001; **, P,0.01; *, P,0.05; n.s., not significant). B) Heterogeneity of colony size on agar plates. Similar data
were obtained for two independent in vitro cultures and five independent ex vivo cultures.
doi:10.1371/journal.pone.0042007.g004
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10 mM glucose-6-phosphate (gutQ yrbH). Agar plates containing
oleate were always freshly prepared and maintained at 37uC to
keep oleate homogeneously dispersed. Minimal inhibitory con-
centrations (MIC) for enrofloxacin were determined as described
[46].
Mouse Infections
All animals were handled in strict accordance with good animal
practice and all animal work was approved by local animal care
and use committee (license 2239, Kantonales Veterina¨ramt BS).
Eight to 12 weeks old female BALB/c mice were infected
intravenously with 106 CFU Salmonella from late exponential LB
cultures. For some experiments, we administered enrofloxacin
(2 mg/ml) in the drinking water beginning two days post infection
[21], or thiolactomycin (two doses of 2 mg per mouse). For
competitive infections, mutant Salmonella carrying different antibi-
otic resistance cassettes were mixed before administration. The
actual bacterial dose was confirmed by plating. At various time
intervals post infection, mice were sacrificed, spleen and liver
collected aseptically in 1 ml of 0.1% Triton Tx-100, and number
of viable bacteria per organ was determined by plating tissue
homogenates on appropriate selective media. Competitive indices
(CI = output ratio/input ratio) were calculated based on plate
counts for inoculum and tissue homogenates collected at seven
days post infection.
In Silico Modeling
To predict additional targets, we used a genome-scale
computational Salmonella in vivo metabolism model STMv1.1, an
updated version of the consensus genome-scale metabolism
reconstruction STMv1 [37] (manuscript in preparation). We used
production of unsaturated fatty acids as objective function and
determined all genes that were predicted to be essential for this
function with Flux-Balance Analysis [36] using MatLab and the
COBRA toolbox [47].
Supporting Information
Figure S1 Colonization kinetics of various Salmonella
mutants in spleen (open circles) and liver (closed circles)
of systemically infected BABL/c mice. A) Colonization of
wildtype Salmonella SL1344 after systemic infection with 350 CFU.
B) Colonization of SL1344 purA after infection with 1.856106
CFU and SL1344 ssaGH after infection with 1.26106 CFU. C)
Initial colonization of SL1344 purA ssaGH after infection with
8.56105 CFU. Statistical significance of colonization level
differences at day 2 and 4 (for data in A), clearance at day 7
compared to day 1 (for data in B), or colonization levels at 24 h
compared to 2 h (for data in C) were determined by t-test of log-
transformed data (***, P,0.001; **, P,0.01; *, P,0.05).
(TIF)
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